title: The new era of hepatitis C virus therapy.
abstract: The hepatitis C virus (HCV) has a significant medical and economic impact on societies around the world, and it has been estimated that 130-180 million people are infected with HCV. Therapies for HCV are currently undergoing a revolution. In recent years, several new treatments have been approved by the United States Food and Drug Administration, and many other treatments are in phase II or III clinical trials, including direct antiviral agents (DAAs). Due to recent major advances in the field of HCV therapy, a summary of findings on new HCV therapies are provided in this review article, including reports on new DAAs.
authors.affiliation: Department of Medicine, Multi-Organ Transplant Unit, Western University, London, Ontario, Canada; Department of Medicine, Division of Gastroenterology, King Saud University, Riyadh, Saudi Arabia, .
authors.forename: Bandar
authors.initials: B
authors.lastname: Al-Judaibi
mesh_terms: D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology; D006801:Humans; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use; D015995:Prevalence; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology
chemical_list: D000998:Antiviral Agents; D019384:Nucleic Acid Synthesis Inhibitors; D015842:Serine Proteinase Inhibitors